Nurix Therapeutics (NASDAQ:NRIX) Upgraded by Leerink Partnrs to “Hold” Rating

Leerink Partnrs upgraded shares of Nurix Therapeutics (NASDAQ:NRIX) to a hold rating in a report issued on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q1 2025 earnings at ($0.89) EPS and Q2 2025 earnings at ($0.93) EPS.

A number of other equities research analysts have also recently commented on NRIX. Morgan Stanley raised their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 3rd. Royal Bank of Canada raised their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. BMO Capital Markets began coverage on Nurix Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $35.00 price objective for the company. Needham & Company LLC cut their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Finally, HC Wainwright raised their price objective on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.88.

Nurix Therapeutics Stock Down 1.9 %

NASDAQ:NRIX opened at $13.66 on Monday. The business’s 50-day simple moving average is $17.33 and its two-hundred day simple moving average is $20.98. The stock has a market cap of $1.04 billion, a PE ratio of -4.73 and a beta of 2.18. Nurix Therapeutics has a 52 week low of $11.90 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Sell-side analysts anticipate that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Houte Hans Van sold 5,825 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $488,660.76. This trade represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,326 shares of company stock worth $213,449 over the last 90 days. Company insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. FMR LLC raised its stake in shares of Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company’s stock valued at $200,349,000 after acquiring an additional 10,047,329 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Nurix Therapeutics by 8.3% during the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company’s stock valued at $81,865,000 after acquiring an additional 333,452 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Nurix Therapeutics by 3.0% during the fourth quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company’s stock valued at $67,572,000 after acquiring an additional 104,500 shares in the last quarter. Soleus Capital Management L.P. raised its stake in shares of Nurix Therapeutics by 97.3% during the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock valued at $39,617,000 after acquiring an additional 1,036,999 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Nurix Therapeutics by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company’s stock valued at $29,870,000 after acquiring an additional 137,087 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.